Active Ingredient(s): Copanlisib
FDA Approved: * September 14, 2017
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Aliqopa Overview

Copanlisib (trade name Aliqopa /ælkop/ AL-ih-KOH-pah;[1] codenamed BAY 80-6946) is a drug which is approved by US FDA for the treatment of adult patients experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.[2] Copanlisib has been shown to have an effect against survival and spread of cancerous B-cells. Efficacy resulting in the approval of copanlisib was based on the subgroup of 104 patients with follicular lym...

Read more Aliqopa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Aliqopa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 60mg
  • Powder: 60mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Aliqopa: (1 result)

Sorted by National Drug Code
  • 50419-385 Aliqopa 15 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Bayer Healthcare Pharmaceuticals Inc.

Other drugs which contain Copanlisib or a similar ingredient: (1 result)